Maxim Sees Major Upside In These Biotech Stocks

Loading...
Loading...

In a recent report, analysts at Maxim Group discussed the biotechnology sector and gave their outlook for five names in the space. Here's a rundown of what they had to say.

Athersys, Inc. ATHX

Analysts believe that Athersys may have found a "sweet spot" for stroke treatment timing, as data from a phase II trial of MultiStem treatment one to two days after a stroke event is expected soon. Maxim has a Buy rating on Athersys and a $9.00 target for the stock.

Cytori Therapeutics Inc CYTX

Cytori recently announced an emphasis on cost-cutting initiatives as it moves forward with its adipose-derives regenerative cell (ADRC) treatment trials. Analysts see big potential for the company in the scleroderma treatment space. Maxim has a Buy rating on Cytori and a $7.00 price target for the stock.

Ocata Therapeutics Inc OCAT

Analysts like the fundamental science and technology that Ocata brings to the table, but they are concerned about the near-term funding risk the company faces after it failed to close a $50 million funding raise in late 2014. Maxim has a Hold rating on Ocata.

OncoSec Medical Inc ONCS

Analysts like the results that OncoSec has seen so far in using up regulation of IL12 to drive cytotoxic T cells to attack tumors. Maxim has a Buy rating on OncoSec and a $3.00 target for the stock.

Tekmira Pharmaceuticals Corp TKMR

Maxim believes that the company is undervalued following its merger with OnCor. Maxim's Buy rating and $27.00 price target for Tekmira is based on an average of sum-of-the-parts, free cash flow and discounted cash flow valuation models.

Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechLong IdeasAnalyst RatingsTrading IdeasGeneralMaxim
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...